2017
DOI: 10.3390/molecules22020217
|View full text |Cite
|
Sign up to set email alerts
|

A Novel Convergent Synthesis of the Potent Antiglaucoma Agent Tafluprost

Abstract: Tafluprost (AFP-168, 5) is a unique 15-deoxy-15,15-difluoro-16-phenoxy prostaglandin F2α (PGF2α) analog used as an efficacious ocular hypotensive agent in the treatment of glaucoma and ocular hypertension, as monotherapy, or as adjunctive therapy to β-blockers. A novel convergent synthesis of 5 was developed employing Julia–Lythgoe olefination of the structurally advanced prostaglandin phenylsulfone 16, also successfully applied for manufacturing of pharmaceutical grade latanoprost (2), travoprost (3) and bima… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
4
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 12 publications
(4 citation statements)
references
References 36 publications
0
4
0
Order By: Relevance
“…α,α‐Difluoro‐γ‐lactone 38 is a fluorinated analogue of a sex pheromone of the male African sugarcane borer, Eldana saccharina , and 38 exhibited a slightly higher pheromone activity compared to the natural pheromone [46] . Matsumura and co‐workers developed the gem ‐difluorinated prostaglandin analogue 39 (Taflprost) [47] which is currently used as the most powerful medicine of glaucoma [47,48] . Gemcitabine ( 40 ) is a gem ‐difluorinated nucleoside analogue and a potent anti‐cancer activity was reported for this compound [49] .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…α,α‐Difluoro‐γ‐lactone 38 is a fluorinated analogue of a sex pheromone of the male African sugarcane borer, Eldana saccharina , and 38 exhibited a slightly higher pheromone activity compared to the natural pheromone [46] . Matsumura and co‐workers developed the gem ‐difluorinated prostaglandin analogue 39 (Taflprost) [47] which is currently used as the most powerful medicine of glaucoma [47,48] . Gemcitabine ( 40 ) is a gem ‐difluorinated nucleoside analogue and a potent anti‐cancer activity was reported for this compound [49] .…”
Section: Introductionmentioning
confidence: 99%
“…[46] Matsumura and co-workers developed the gem-difluorinated prostaglandin analogue 39 (Taflprost) [47] which is currently used as the most powerful medicine of glaucoma. [47,48] Gemcitabine ( 40) is a gem-difluorinated nucleoside analogue and a potent anti-cancer activity was reported for this compound. [49] KAG-308 (41) was developed as medicine for treating ulcerative colitis with a lower risk of colorectal carcinogenesis.…”
Section: Introductionmentioning
confidence: 99%
“…Meanwhile, the proportion of fluorine-containing pharmaceuticals in commercial pharmaceuticals has exceeded 20% . However, pharmaceuticals with gem -difluoroallylic moieties, such as Glecaprevir, Tafluprost, and so forth, accounted for a very low proportion in known fluorine-containing pharmaceuticals, which was related to the lack of efficient synthetic approaches for such construction. , Several recent studies have focused on the synthesis of functionalized Z -allylic building blocks with gem -difluoromethylene motifs, which will undoubtedly speed up and facilitate the construction of pharmaceutically interesting molecules and advanced materials. However, the methods to access these specific skeletons are mainly finite to the semihydrogenation and diverse cross-coupling of relatives with organometallics under certain conditions (Scheme a) . Inherently, all of these strategies rely on kinetic controls and the use of specific reagents. On the other hand, photoredox catalysis with various photosensitizers has played an important role and been recognized as an efficient green process and stimulated numerous contributions of advances for the C–C bond coupling in organic synthesis in the past 2 decades. Nevertheless, not many successful cases of the photo-induced electron transfer (PET) process for the construction of organofluorine molecules have been reported yet (Scheme b,c). , …”
Section: Introductionmentioning
confidence: 99%
“…Tafluprost, developed by Asahi Glass Co., Ltd., and Santen Pharmaceutical Co., is Santen’s and Merck Sharp & Dohme’s prostaglandin PGF 2 α analogue for the treatment of intraocular pressure in open-angle glaucoma and ocular hypertension . Previous syntheses of Tafluprost ( 1 ) have relied on the Corey lactone to access the densely functionalized cyclopentane core. , …”
mentioning
confidence: 99%